Or. Admin. Code § 410-121-0420
Current through Register Vol. 63, No. 11, November 1, 2024
Section 410-121-0420 - DESI Less-Than-Effective Drug List(1) An October 23, 1981 ruling by District of Columbia Federal Court directed the Department of Health and Human Services to stop reimbursement, effective October 30, 1981, under Medicaid and Medicare Part B for all DESI less-than-effective drugs which have reached the Federal Drug Administration Notice-of-Opportunity-for-Hearing stage.(2) In accordance with Section 1903(i)(5) of the Social Security Act, federal funds participation (FFP) is not available for drugs deemed Less Than Effective (LTE) or Identical, Related of Similar (IRS) drugs for which the Food and Drug Administration (FDA) issued a Notice of Opportunity for a Hearing (NOOH) for all labeled indications. These drugs are also termed Drug Efficacy Study Implementation (DESI) drugs. Division does not reimburse for drugs designated as less than effective or drugs identical, related, or similar to a DESI drug.(4) The US Food & Drug Administration (FDA) has the responsibility of determining the DESI status of a drug product.Or. Admin. Code § 410-121-0420
AFS 56-1989, f. 9-28-89, cert. ef. 10-1-89; AFS 64-1989(Temp), f. 10-24-89, cert. ef. 11-15-89; AFS 79-1989, f. & cert. ef. 12-21-89; HR 17-1990(Temp), f. 6-29-90, cert. ef. 7-1-90; HR 29-1990, f. 8-31-90, cert. ef. 9-1-90, Renumbered from 461-016-0390; HR 20-1991, f. & cert. ef. 4-16-91; HR 20-1994, f. 4-29-94, cert. ef. 5-1-94; OMAP 1-1999, f. & cert. ef. 2-1-99; OMAP 29-2000, f. 9-29-00, cert. ef. 10-1-00; OMAP 18-2004, f. 3-15-04 cert. ef. 4-1-04; DMAP 39-2009, f. 12-15-09, cert. ef. 1-1-10; DMAP 38-2018, minor correction filed 05/25/2018, effective 5/25/2018; DMAP 96-2022, amend filed 12/28/2022, effective 1/1/2023Statutory/Other Authority: ORS 413.042 & 414.325
Statutes/Other Implemented: ORS 414.065